EN
Home/Answers/GLP-1 medicines and menopause
ALLAll countries Medicines

Do tirzepatide and semaglutide help with menopause?

What we checked17 sources, each one opened and linked to the sentence it supportsLast checked Nov 9, 2026 · Next review due Nov 8, 2027 · How we write
The short answer

Tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy) lower weight around menopause, but we found no completed trial showing relief of hot flushes. The US Zepbound and Wegovy labels do not list menopause as a use. In a SURMOUNT-1 analysis, postmenopausal women lost 23% on tirzepatide versus 3% on placebo. Nausea is common.

Do tirzepatide and semaglutide cause weight loss around menopause?

Women in trial analyses lost weight on tirzepatide and semaglutide at every menopausal stage, but these analyses were not designed to compare stages.12 Perimenopause is the time before menopause, when periods may become irregular, lighter or heavier.16

In SURMOUNT-1, women in this analysis took tirzepatide 15 mg. Over 72 weeks, they lost 23% of body weight in perimenopause and after menopause, compared with 3% on placebo.1 For a 90 kg woman, 23% is about 21 kg, a trial average, not a forecast.

The paper's results section gives 24% to 26%, without explaining the gap. Stomach side effects were the most common harms.1

For semaglutide 7.2 mg, Novo Nordisk announced 72-week losses of 19.7% in perimenopause and 19.8% after menopause, if all women stayed on treatment. This after-the-trial (post hoc) analysis gave no placebo figures.2

Do they ease hot flushes and other menopause symptoms?

We found no completed trial showing tirzepatide or semaglutide eases hot flushes, so symptom relief on these medicines remains unproven.34

The US Zepbound and Wegovy labels do not list menopause as a use.911

A 2026 scoping review said these medicines may help hot flushes. Its support was a conference abstract, and the authors called the evidence limited.3 Novo Nordisk also announced a 25% lower depression risk with Wegovy than with hormone therapy alone. It was a real-world study, not a randomised trial.2

A Mayo Clinic pilot is measuring tirzepatide's effect on hot flush frequency and severity in an estimated 40 postmenopausal women. No results are posted.4

Do tirzepatide and semaglutide affect HRT?

Slower stomach emptying may reduce absorption of oral hormone replacement therapy (HRT), so British Menopause Society guidance prefers non-oral progestogen during tirzepatide or semaglutide.5 We read it in summaries.56 Progestogen is the part of HRT that protects the womb lining.6

The guidance calls a 52 mg levonorgestrel coil likely the preferred option.56

The guidance prefers oestrogen through the skin for women with obesity and diabetes, including those on these medicines. Oral oestrogen further raises clot risk. Bleeding that continues after a progestogen change needs checking to rule out womb lining disease.6

In a conference report of records from 3,855 women, semaglutide users on HRT lost 11.0% at 12 months, compared with 9.5% without it. For tirzepatide, average weight loss showed no significant difference after month 3.7

A smaller Mayo Clinic records study of 120 women on tirzepatide reported 19.2% with HRT and 14.0% without, but it was not randomised.815 The larger study does not support prescribing HRT to boost weight loss.7

Tirzepatide may make the contraceptive pill less reliable. The US Zepbound label advises a non-oral method. Another option is a barrier method for 4 weeks after starting and after each dose increase. The UK Mounjaro SmPC (the UK product information) gives this advice for women with obesity or overweight.910

What are the risks of tirzepatide and semaglutide?

Nausea, diarrhoea and constipation are common, and the US Zepbound and Wegovy labels both warn about pancreatitis and gallbladder disease.911

The US Zepbound and Wegovy labels carry a boxed warning about thyroid C-cell tumours. The US Zepbound label says weight loss is not recommended during pregnancy.911

On the US Zepbound label, nausea affected 25% to 29% of people, compared with 8% on placebo.9 On the US Wegovy label, nausea affected 39% in the 7.2 mg trials, compared with 13% on placebo.11

These figures come from separate trials, so they cannot rank the medicines. See your country's side-effects guide.

What do people on GLP-1 medicines report about menopause?

From public patient forums: 199 Reddit threads in r/Zepbound, r/mounjarouk, r/LadiesHRTwithGLP1, r/Mounjaro, r/Semaglutide and r/WegovyWeightLoss, posted October 2025 to October 2026. Personal reports, not medical evidence.

What people describe

  • Matches the trial Many describe weight loss in perimenopause or after menopause.1
  • Not studied Several say hot flushes, night sweats or brain fog eased on a GLP-1 medicine. Several others say symptoms did not improve, worsened or returned during weight loss. We found no completed trial.
  • Not studied Many say taking HRT alongside a GLP-1 medicine caused no noticeable problem. Several describe stronger hunger, a stall or lasting gain after starting HRT. We found no randomised trial of this. The records studies above reported average weight loss, not hunger or side effects.
  • Matches the guidance Several worry that slowed stomach emptying reduces absorption of oral progesterone.5
  • Not studied after menopause Several describe new spotting, bleeding or returning periods on a GLP-1 medicine, sometimes after adding HRT. We found no study giving results for bleeding after menopause on these medicines. US adverse-event reports in women aged 12 to 55 flagged bleeding between periods on semaglutide and tirzepatide, but such reports cannot show cause.17 The NHS lists HRT as one possible cause of bleeding after menopause and says any such bleeding needs a GP check.12

Advice people share

  • Not studied Several advise strength training and enough protein. We found no completed trial of this in postmenopausal women on these medicines. A 2026 scoping review said effects on osteoporosis need more research.3
  • Matches the guidance Several advise asking about non-oral HRT or a progestogen coil.56
  • Label says otherwise Several posts describe stretching the time between injections or splitting doses. The US Zepbound label gives set once-weekly doses.9

In your country

The evidence above is the same everywhere, while the brands sold and the labels we could open differ by country. Semaglutide 7.2 mg is listed only for Germany, the UK and the US.

Australia

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill treated as not approved). Semaglutide tablets, diabetes: Rybelsus approved; whether supplied not confirmed.

Label: We could not open Australia's Product Information for this page. The answer above relies on the US Zepbound and Wegovy labels and the UK Mounjaro SmPC.

Emergency number: 000

Side effects guide for Australia

Canada

Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen, Zepbound. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Semaglutide Injection (Dr. Reddy’s; shortage reported Jul 2026, lots recalled Aug 2026); Apo-Semaglutide (one lot recalled Aug 2026). Semaglutide tablets, weight: none (no oral Wegovy in Health Canada’s drug database). Semaglutide tablets, diabetes: Rybelsus. Semaglutide approved but not marketed: Sevmia, Poviztra, Plosbrio, Aspen-Semaglutide, Semaglutide Injection (Aspen), Sandoz Semaglutide.

Label: We could not open Canada's Product Monographs for this page. The answer above relies on the US Zepbound and Wegovy labels and the UK Mounjaro SmPC.

Emergency number: 911

Side effects guide for Canada

France

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill not sold in France). Semaglutide tablets, diabetes: none found (Rybelsus not in France’s medicines database).

Label: We could not open the EU labels for this page. The answer above relies on the US Zepbound and Wegovy labels and the UK Mounjaro SmPC.

Emergency number: 15 or 112

Side effects guide for France (in French)

Germany

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy Tablette. Semaglutide tablets, diabetes: Rybelsus.

Label: We could not open the EU labels for this page. The answer above relies on the US Zepbound and Wegovy labels and the UK Mounjaro SmPC.

Emergency number: 112

Side effects guide for Germany (in German)

India

Sold as: Tirzepatide: Mounjaro, Yurpeak. Semaglutide injection, weight: Wegovy; Poviztra; Noveltreat. Semaglutide injection, diabetes: Ozempic; Obeda (Dr Reddy’s; recalled Jul 2026 over an active-ingredient impurity; on 23 Oct 2026 the company said it planned to relaunch in Nov; resumption not confirmed at 8 Nov 2026; distributors told Reuters it may be discontinued); Sematrinity; GLIPIQ; Semalix (batches recalled Jul 2026); Semanat; Semafull. Semaglutide injection, diabetes and weight: Semaglyn; Mashema; Alterme; Semasize; Obesema; Hepaglide. Semaglutide, diabetes and weight (form not confirmed): Obeda Pro; Obeda Plus (Dr Reddy’s, made by Hetero Labs; in the market from late Jul 2026). Semaglutide injection, use not confirmed: Semanext; Livarise; Sundae. Semaglutide, form and use not confirmed: Samakind; Usema (batches recalled). Semaglutide tablets, weight: not confirmed. Semaglutide tablets, diabetes: Rybelsus; Sembolic; Obeda (tablets not part of the Jul 2026 recall).

Label: We could not open an Indian label for this page. The answer above relies on the US Zepbound and Wegovy labels and the UK Mounjaro SmPC.

Emergency number: 112

Side effects guide for India

Saudi Arabia

Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Tasylev; Lugyda; Glucentra. Semaglutide tablets, weight: none (Wegovy pill not registered). Semaglutide tablets, diabetes: Rybelsus.

Label: We could not open a Saudi label for this page. The answer above relies on the US Zepbound and Wegovy labels and the UK Mounjaro SmPC.

Emergency number: 997 or 911

Side effects guide for Saudi Arabia (in Arabic)

United Arab Emirates

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Rybelsus.

Label: We could not open a UAE label for this page. The answer above relies on the US Zepbound and Wegovy labels and the UK Mounjaro SmPC.

Emergency number: 998 for an ambulance, or 999

Side effects guide for the UAE

United Kingdom

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy tablets (authorised 11 Jun 2026; retail sale not confirmed). Semaglutide tablets, diabetes: Rybelsus.

Label: The UK Mounjaro SmPC limits its advice on the pill to women with obesity or overweight, and says no oral contraceptive dose adjustment is needed at normal BMI.10 The answer above relies on the US Zepbound and Wegovy labels and the UK Mounjaro SmPC. We did not open the UK Wegovy injection SmPC.

Emergency number: 999

Side effects guide for the UK

United States

Sold as: Tirzepatide: Zepbound, Mounjaro. Semaglutide injection, weight: Wegovy, including Wegovy HD 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Ozempic tablets; Rybelsus (being discontinued).

Label: The answer above applies.

Emergency number: 911

Side effects guide for the US

Get help now: call your local emergency number Severe stomach pain or pressure, severe or persistent vomiting or diarrhoea, trouble breathing, swelling of the face, eyes or tongue, fainting, bleeding that will not stop, or thoughts of suicide.13 Emergency numbers: 911 in the US and Canada, 999 in the UK, 998 or 999 in the UAE, 000 in Australia, 112 in India and Germany, 15 or 112 in France, 997 or 911 in Saudi Arabia.

Get any vaginal bleeding after menopause checked by a GP or doctor, even if it happened once.12 Contact a doctor urgently if you notice a change in your eyesight on semaglutide.14

Read the full picture

Related questions

Did this answer your question?

Sources

  1. Tchang BG, et al. Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program. Obesity, 2025. PMC12015656
  2. Novo Nordisk company announcement, 12 May 2026, on data at the European Congress on Obesity, including a post hoc STEP UP analysis. Copy carried by Inderes. Release
  3. Graczyk NA, Bisschops J. Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) for Obesity and Symptoms in Menopause: A Review. Cureus, 2026. PMC12908505
  4. Mayo Clinic. The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity: A Pilot Study. NCT07218445
  5. GPnotebook summary of British Menopause Society guidance, Use of incretin-based therapies in women using HRT, April 2025. We could not open the original. Summary
  6. Diggle J. Diabetes on the Net, 10 September 2025: summary of British Menopause Society guidance updated 19 May 2025. Summary
  7. Patient Care Online, 22 October 2026: report of Castaneda R, et al., The Menopause Society 2026 Annual Meeting. Report
  8. Consultant360: report of Castaneda R, et al. The Lancet Obstetrics, Gynaecology, & Women's Health, 2026. DOI 10.1016/S3050-5038(25)00145-1. We could not open the paper itself. Report
  9. US Zepbound (tirzepatide) prescribing information, Eli Lilly, revised 8/2026. US label
  10. UK Mounjaro KwikPen (tirzepatide) SmPC, emc, updated 8 September 2026. UK SmPC
  11. US Wegovy (semaglutide) prescribing information, Novo Nordisk, revised 6/2026. US label on DailyMed
  12. NHS. Post-menopausal bleeding. Reviewed 24 September 2026. NHS page
  13. MedlinePlus. Recognizing medical emergencies, listing American College of Emergency Physicians warning signs. Reviewed 8 January 2025. MedlinePlus page
  14. MHRA. GLP-1 medicines for weight loss and diabetes: what you need to know. Updated 5 February 2026. MHRA guidance
  15. EurekAlert news release on the same Mayo Clinic tirzepatide study, quoting senior author Maria Daniela Hurtado Andrade. News release
  16. NHS. Menopause: symptoms. Reviewed 19 May 2026. NHS page
  17. Contemporary OB/GYN: report of Frey C, Etminan M. Obstetrics & Gynecology, 20 July 2026. Report

Last checked Nov 9, 2026 · Next review due Nov 8, 2027 · Report an error

How this answer was made. Written by the GLP Guidebook team from the sources above, all checked by Nov 9, 2026. The “What people report” section summarises public patient forum posts we read; it is not medical evidence, and we never pass on advice that goes against the label. It’s general information, not medical advice. Talk to a doctor, pharmacist or other licensed prescriber before starting, stopping or changing any medicine. In an emergency, call your local emergency number. How we write